Indication

Posttraumatic Stress Disorder

21 registered trials testing Psilocybin, MDMA, Ketamine for this indication, 4 recruiting now.

Registered trials

Recruiting

In Phase 3

Substances tested

Being studied with

Stay told

When a new trial opens

Trials

All 21 trials for Posttraumatic Stress Disorder

Trial	Status	Phase	Substance	Sites
Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSDNCT06608277 · Northwestern University	Recruiting	Phase 2	ketamine	3
Dose Optimization of MDMA-Assisted Therapy for PTSDNCT06418178 · Bronx VA Medical Center	Recruiting	Phase 2	mdma	1
Enhancing Week-long Psychological Treatment for PTSD With KetamineNCT05737693 · Yale University	Recruiting	Phase 2	ketamine	2
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)NCT06989957 · Johns Hopkins University	Recruiting	Phase 1	psilocybin, mdma	1
RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn PainNCT03305055 · Johns Hopkins University	Terminated	Phase 4	ketamine	1
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)NCT03537014 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	15
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)NCT04077437 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	14
Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)NCT03485287 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	2
MDMA-Assisted Psychotherapy in People With Posttraumatic Stress DisorderNCT00090064 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	1
Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - IsraelNCT00402298 · Resilient Pharmaceuticals	Terminated	Phase 2	mdma	1
Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress DisorderNCT01211405 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	1
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSDNCT01793610 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	1
Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSDNCT01958593 · Resilient Pharmaceuticals	Terminated	Phase 2	mdma	1
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSDNCT02876172 · Resilient Pharmaceuticals	Completed	Phase 1 / Phase 2	mdma	1
Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSDNCT04968938 · Resilient Pharmaceuticals	Withdrawn	Phase 2	mdma	—
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress DisorderNCT00353938 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	1
Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy TrialNCT01458327 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	1
Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure TherapyNCT02727998 · Yale University	Terminated	Phase 2	ketamine	1
CAP-Ketamine for Antidepressant Resistant PTSDNCT02655692 · VA Office of Research and Development	Completed	Phase 2	ketamine	3
Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)NCT06378528 · University of Wisconsin, Madison	Suspended	Early Phase 1	ketamine	1
Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSDNCT02102802 · Resilient Pharmaceuticals	Completed	N/A	mdma	1

Records from ClinicalTrials.gov API v2, data build 2026-08-25. Indications are the sponsors’ own words. LSD.com reports registered clinical research. It is not medical advice, it is not a recommendation to take any substance, and trial listings are not endorsements. Talk to a clinician.